CAMBO-VIP for advanced diffuse large cell lymphoma (LSG classification) - A long term follow-up study

M. Okamoto, F. Maruyama, M. Tsuzuki, T. Nomura, H. Miyazaki, M. Wakita, H. Kojima, R. Sobue, T. Matsui, T. Ino, K. Ezaki, M. Hirano

Research output: Contribution to journalArticlepeer-review


Twenty-two patients with advanced diffuse large cell lymphoma (LSG classification) were treated with the combination chemotherapy of cyclophosphamide, doxorubicin, methotrexate with leucovorin rescue, bleomycin, vincristine, etoposide, ifosfamide and prednisolone (CAMBO-VIP) from Oct. 1987 to Sept. 1989. Eighteen (90%) of 20 evaluable patients achieved complete remission and 2 patients had partial remission. With a median follow-up of 52 mos, 3 patients relapsed (17%), and 2 patients died. The actuarial overall survival and relapse-free survival at 4 years were estimated to be 90% and 83%, respectively. Myelosuppression was severe, but transient. No serious infection was seen, and no platelet transfusion was required. Oral mucositis and liver damage (Grade 3 in WHO grading) was seen in one patient each, but no treatment-related fatalities were observed. CAMBO-VIP is a well tolerated, effective treatment regimen for advanced diffuse large cell lymphoma.

Original languageEnglish
Pages (from-to)67-73
Number of pages7
JournalJapanese Journal of Cancer and Chemotherapy
Issue number1
Publication statusPublished - 1994

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'CAMBO-VIP for advanced diffuse large cell lymphoma (LSG classification) - A long term follow-up study'. Together they form a unique fingerprint.

Cite this